1/27/2015 9:19 AM IPN.PA 45.09 € (-0.53 %) Data: Yahoo Finance
Startsidan

Press Releases

  • 1/26/2015

    Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults

    Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults
  • 1/7/2015

    Ipsen announces its corporate agenda for 2015

    Ipsen announces its corporate agenda for 2015
  • 12/16/2014

    Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors

    Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors
  • 12/16/2014

    François Garnier appointed Executive Vice President, General Counsel of Ipsen

    François Garnier appointed Executive Vice President, General Counsel of Ipsen
  • 12/12/2014

    Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen

    Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen
  • 11/28/2014

    Ipsen announces FDA acceptance of filing for Dysport® in the treatment of upper limb spasticity in adult patients

    Ipsen announces FDA acceptance of filing for Dysport® in the treatment of upper limb spasticity in adult patients
  • 11/20/2014

    Ipsen and CNRS create the “Archi-Pex” joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA

    Ipsen and CNRS create the “Archi-Pex” joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA
  • 11/18/2014

    Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences

    Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences
  • 11/6/2014

    Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus

    Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus
  • 10/29/2014

    Ipsen: sales in the 3rd quarter and first nine months of 2014

    Ipsen: sales in the 3rd quarter and first nine months of 2014